Salute e Benessere

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900…

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“ORR”) in evaluable anti-PD-1 naïve patients per RECIST 1.174% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.115.5 months median Overall Survival (“mOS”) in evaluable anti-PD-1 naïve patients11.4 months mOS in...

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first…

The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly...

DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology…

Key Takeaways from the DNA Synthesis Inhibitors Market Report Key Takeaways from the DNA Synthesis Inhibitors Market Report Discover which indication is expected to grab the major DNA synthesis inhibitors market share @DNA Synthesis Inhibitors Market Report Key Factors Driving the DNA Synthesis Inhibitors Market Rising clinical demand — oncology & genetic disease DNA-synthesis inhibitors remain core components of many chemotherapy regimens and are being actively...

uniQure Announces Closing of Upsized Public Offering and Full Exercise by…

uniQure intends to use the net proceeds from this offering to fund its commercialization readiness activities, the potential commercial launch of AMT-130 and related commercialization activities, the development of its other clinical product candidates, business development initiatives and research projects, and for general corporate purposes.Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen acted as bookrunning managers for the offering. H.C. Wainwright & Co...

Surgical Staplers Market To Grow US$ 10,587.21 Million By 2033, Registering A…

Technology is currently evolving with the development of smart staplers that incorporate feedback and sensors that provide the surgeon with in-situ data on the properties of the tissue being stapled, which reduces complications such as leakage. Cross-pollination between stapling technologies and robotic-assisted surgical systems is a growing trend that will enhance surgeons' abilities to perform conventional surgery and work effectively with stapling instrumentation, offering greater…

Vantage Market Research: Global Companion Diagnostics Market Size & Share to…

Market Highlights Market Highlights Key Regional Markets Leading the Way Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making. Access the Full Study Instantly | Download Sample Pages of the Report Now@ https://www.vantagemarketresearch.com/companion-diagnostics-market-2021/request-sample Free Sample Includes: Technological & Industry Momentum Why...

FAMAR Group: Dr. Riku Rautsola Appointed New CEO

At the same time, FAMAR Group is pleased to announce the appointment of Dr. Riku Rautsola as CEO, effective September 29, 2025. Riku has served as a non-executive member of FAMAR's Board of Directors and an advisor to MidEuropa during the acquisition of FAMAR last year. Riku is a globally experienced leader in the pharmaceutical, biotech and CDMO industries, having held CEO and senior executive positions at several leading companies, creating sustained profitable growth At the same time…

IHH Healthcare Expands Collaboration with Leo Cancer Care to Advance Upright…

Proton therapy has long been recognised for its precision in targeting tumours, but adoption has been limited by the size, cost, and infrastructure demands of conventional systems. By rotating the patient rather than the beam, Leo Cancer Care's upright approach dramatically reduces system size and cost, creating a future where proton therapy is within reach for more patients. Proton therapy has long been recognised for its precision in targeting tumours, but adoption has been limited by the...

Fagron increases share capital through exercise subscription rights

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 355,000 new shares have been issued on 29 September 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 506,745,841.93. The total number of shares with voting rights after the...

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the…

With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France – September 29, 2025, 6.30 pm CEST – THX Pharma (formerly Theranexus), a pharmaceutical company specializing in rare neurological diseases, today unveils its new…

Czech Innovation Against Alzheimer's: H2 Global Group Enters Key Growth Phase

"Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence," explains Prof. Ohta. "Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,"explains Prof. Ohta. Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds:"Our mission is to launch the world's first hydrogen-based medical device for Alzheimer's…

Interventional Cardiology Devices Market to Reach US$39,234.52 million by 2033…

The opening of more cardiac centers and outpatient cath labs, particularly in developing countries, will also drive market growth. There is a significant opportunity in developing devices that can treat complex heart conditions and in expanding into regions where advanced treatments are currently unavailable. However, the high cost of these devices can slow down adoption, especially in low-income countries. Strict approval rules for new products and a shortage of trained specialists in certain…

DMS GROUP : SUSTAINED GROWTH IN HALF-YEAR RESULTS FOR 2025

New half-year of business growth (+3%) in the 1st half of 2025, in a demanding international environment Strong EBITDA growth of +82% - EBITDA margin of 7.2% (vs. 4.1%) +€1.2 million improvement in net income group share Outlook: confirmation of the objective of accelerating growth in the 2nd half of 2025 in a less dynamic market context September…

Laboratory Equipment Market is expected to generate a revenue of USD 41.13…

The Laboratory Equipment Market is expanding rapidly due to rising healthcare demands, technological upgrades, and increased pharmaceutical R&D. Growing focus on automation, advanced diagnostics, and cost-effective testing is reshaping opportunities for manufacturers and suppliers worldwide. The Laboratory Equipment Market is expanding rapidly due to rising healthcare demands, technological upgrades, and increased pharmaceutical R&D. Growing focus on automation, advanced diagnostics…

Consortium consisting of Nordic Capital and Permira extends offer period until…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, September 29, 2025– With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document " ) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and…

Practice Management Systems Market is Projected to Reach US$36.33 billion at…

Practice Management Systems Market Set to Soar with Demand for Healthcare AutomationValued at US$ 19.65 billion in 2024. The market is projected to reach US$ 36.33 billion by 2031, registering a strong CAGR of 9.3% (2025–2031). The growth has been driven mainly due to the rising need for digital healthcare solutions, the higher number of patients, and the necessity for efficiently managing administrative processes. Practice Management Systems Market Set to Soar with Demand for Healthcare...

Pierre Fabre Laboratories Announces Global Partnership with Know Your Lemons…

Founded in 2014 by Corrine Ellsworth Beaumont, the Know Your Lemons Foundation focuses on breast cancer education. Inspired by personal experience and professional expertise in health communication, Corrine developed a creative approach using lemons as a visual metaphor. The 12 lemons, each representing a potential symptom of breast cancer, have become the centerpiece of the foundation's educational tools, which include an award-winning mobile app recognized at the 2025 Webby Awards for…

LILYSILK's SILKERRY™ Collection Sells Out in Five Days, Signaling Strong Demand…

The sold-out collection includes three distinctive style lines: Seamflow, Porchlight, and Heirloom '89, available in four neutral colorways. Each line reflects a different facet of modern lifestyles, including city movement, relaxed home living, and timeless sportswear. Signature pieces such as the Seamflow Verge Hoodie and Heirloom '89 Zip Jacket have been praised for their elegance and functionality. The sold-out collection includes three distinctive style lines: Seamflow, Porchlight, and...

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead…

Under the agreement, HHP and Hanmi Pharm ("Hanmi") will grant Gilead exclusive global rights to encequidar within the field of virology. In addition, HHP and Hanmi will provide drug supply, share technical know-how, and participate as key project partners. HHP and Hanmi will each receive an upfront payment and are eligible to receive development, regulatory and sales milestones in addition to low single-digit royalties on net sales. Under the agreement, HHP andHanmi…

New medical writing service QInscribe reduces the time to generate a draft…

"Medical writing can benefit from the AI revolution that is reshaping industries worldwide. It can still uphold the highest quality standards that you would expect, but in a fraction of the time,"saidAmol Hule, Associate Director of Medical Writing at QInscribe."We combine specialist human insight from a team of experienced medical writers with AI-enabled efficiencies to ensure every deliverable is accurate, consistent, and submission-ready." Whereas a draft Clinical...

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the…

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US Basel, September 29, 2025– Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering...

CeraVe and L'Oréal Groupe Win Prestigious IFSCC Applied Research Award for…

"Receiving the IFSCC Applied Research Award is a testament to our joint commitment to scientific innovation and understanding the intricate biology of skin and scalp barrier health," said Gene Colón, Global Senior Vice President, Medical Affairs & Communications for CeraVe at L'Oréal. "This game-changing research moves beyond the traditional view of dandruff to highlight the role of ceramide deficiency and scalp barrier dysfunction, the critical bacterial component and the…

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company’s shareholders.Dear Fellow Shareholders,Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress - refining our strategy, reinforcing our operations, and positioning every business unit...

BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase…

Section 12 of the February 11th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31, 2024. On December 9th, 2024, Horizon and BioVaxys amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025."On May 28th, 2025, Horizon and BioVaxys further amended the APA by agreeing to delete the reference to "December 31…

Altri Comunicati